… pathway and the inhibition causing adverse drug reaction, currently many biologics,
macromolecules, and small molecules that modulate this pathway … inhibitors of the NF-κB pathway …

… Mutations in a kinase encoded on the X chromosome, now termed BTK, were found to be
responsible for XLA. Patients with XLA, as a consequence of defective BCR signaling, lack …

… For instance, tissue factor pathway inhibitor (TFPI) — present on the endothelium and in the
blood — inhibits FXa, FVa and the TF–FVIIa initiating complex 34 . The endothelial protein C …

… COVID-19 specimens, cell-based inhibition studies, and NET/human aortic endothelial cell
(HAEC) cocultures. Increased plasma levels of NETs, tissue factor (TF) activity, and sC5b-9 …

… has been pharmacologically targeted using small molecule inhibitors, TGF-β-directed … now
evaluated in clinical trials. Here, we have assessed the safety and efficacy of TGF-β pathway …

… because of tissue factor exposure. Therefore, blocking both pathways by combining … on
chronic coronary syndromes (CCS) now recommend the addition of a second antithrombotic drug …

… naturally integrated recombinant tissue factor (TF) [Citation22,Citation23]. TT-173 triggers
the extrinsic pathway of the coagulation cascade accelerating clot formation. Up to now, TT-…

… Inflammation-induced coagulation is initiated by the expression of the transmembrane
protein “Tissue Factor” (TF) [69]. In the lung, TF is expressed in alveolar epithelial cells [70], …

… several coagulation factors. ECs express tissue factor pathway inhibitor (TFPI), which limits
the action of tissue factor (TF) and inhibits excessive TF-mediated activation of coagulation …

… protein C, protein S, tissue factor pathway inhibitor, and antithrombin. The substitution
and … We are now on the cusp of a paradigm shift in prophylaxis for hemophilia through the …